United States: The wonder drugs for cancer that could sustain life longer do not work in most terminally ill patients, new research discovered.
Effectiveness of Cancer Treatments in Advanced Stages
Treatments like chemotherapy, immunotherapy, targeted therapy, and hormone therapy do not prolong survival among very seriously ill patients, as the authors of a study published in JAMA Oncology on May 16 found.
Study Findings
“Since we don’t see an improved survival benefit, oncologists should revisit their goals of care conversations with patients, and this information in the study should be explained to patients,” said lead researcher Maureen Canavan, an associate research scientist with Yale Cancer Center, as reported by HealthDay.
The research team used data from more than 78,000 records on adult cancer patients who were treated at 280 U. S. cancer treatment facilities during the period 2015-2019.
Lack of Survival Benefit
In this instance, the research scrutinized the last stages of life of patients of the six most common cancers: breast, colon, lung, pancreas, kidney, and bladder.
Implications for Patient Care
“We wanted to find out if oncologic treatment of very advanced tumors is associated with improved survival or if there are times when it’s futile to continue care and instead oncologists should shift focus to palliative and supportive care,” Canavan said in a Yale news release.
According to an investigator, the results failed to indicate a correlation between the formation of systemic therapies survival rate and that of patients who didn’t receive such treatments.
It was demonstrated that this occurrence was universal to all of the cancer types.
Previous Research Context
This data lays the groundwork for another study published in the same journal, JAMA Oncology, in 2022, which suggests that chemotherapy use decreases at the last stage of a patient’s life.
However, along with the increased use of the latter, there has also been a growth in the application of newer immunotherapy treatments, the earlier research said.
In other words, the overall use of systemic remedies has maintained a stable figure, with just about 17% of terminally ill persons getting their hands on the treatment that is now clear and without meaning, according to researchers.
“We hope this information can help inform oncologists when they are deciding whether or not to continue treatment or transition patients who have metastatic disease to supportive care,” Canavan said.
